Cart
sales@molnova.com
Ipilimumab
CAS No. 477202-00-9
Ipilimumab( —— )
Catalog No. M22137 CAS No. 477202-00-9
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 556 | In Stock |
|
| 5MG | 747 | In Stock |
|
| 10MG | 1216 | In Stock |
|
| 25MG | 2014 | In Stock |
|
| 50MG | 2660 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIpilimumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionIpilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
-
DescriptionIpilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number477202-00-9
-
Formula Weight148 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54.
molnova catalog
related products
-
anemarsaponin B
Anemarsaponin B has anti-inflammatory effect in LPS-treated RAW 264.7macrophages, the effect is associated with the inhibition of NF-κB transcriptional activity, possibly via the p38 MAP kinase pathway.
-
Fusarochromanone
Fusarochromanone (FC-101) is a mycotoxin produced by Fusarium marcescens with potent antiangiogenic, anticancer and antimalarial activities.
-
Bacopaside X
Bacopaside X (9.06 μM) showed binding affinity towards the D1 receptor.
